Key result
Long-term systemic anticoagulant use in hospitalized patients with pancreatic cancer was associated with lower odds of in-hospital mortality (aOR 0.65; 95% CI 0.60-0.70).
Why the study?
Pancreatic cancer induces a hypercoagulable state that can lead to thrombosis, but the effect of anticoagulants remains ambiguous.
Does long-term systemic anticoagulant usage improve in-hospital outcomes in hospitalized adults with pancreatic cancer?
Population
242,903 hospitalized adults with pancreatic cancer
Comparison
Long-term systemic anticoagulant use vs no long-term anticoagulant use
Design
Retrospective propensity score-matched database study
Authors
Loading...
Anticoagulant use was associated with lower inpatient mortality and complications in pancreatic cancer; leaves open whether trials should test routine use.
Cohort (n=242,903)
Yes
Does long-term systemic anticoagulant usage improve in-hospital outcomes in hospitalized adults with pancreatic cancer?
Odds Ratio: 0.65 (95% CI 0.6–0.7)
Long-term systemic anticoagulant use is associated with decreased risks of in-hospital mortality, life-threatening events, and prolonged length of stay among hospitalized patients with pancreatic cancer.
Huang et al. (2023) conducted a cohort in Pancreatic cancer (n=242,903). Long-term systemic anticoagulant use vs. Without long-term systemic anticoagulant use was evaluated on In-hospital mortality (aOR 0.65, 95% CI 0.60-0.70). Long-term systemic anticoagulant use in hospitalized patients with pancreatic cancer was associated with lower odds of in-hospital mortality (aOR 0.65; 95% CI 0.60-0.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: